(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification Number) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Page No. | ||||||||
5 | ||||||||
5 | ||||||||
6 | ||||||||
7 | ||||||||
8 | ||||||||
9 | ||||||||
11 | ||||||||
20 | ||||||||
30 | ||||||||
30 | ||||||||
31 | ||||||||
31 | ||||||||
31 | ||||||||
31 | ||||||||
32 | ||||||||
33 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 3 |
Abbreviation | Description | ||||
2022 Form 10-K | Annual report on Form 10-K for the year ended December 31, 2022 | ||||
Adjusted Income from Operations | Income from Operations adjusted for certain items discussed in Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | ||||
Credit Agreement | Credit Agreement dated September 30, 2021, First Amendment dated April 26, 2022, and Second Amendment dated June 15, 2023, among the Company and certain subsidiaries as borrowers. Bank of America, N.A., as administrative agent, swing line lender, a lender and a letter of credit issuer and the other lenders party thereto, as amended | ||||
Credit Agreement Defined Debt Leverage Ratio | As of any date of determination, the ratio of (a) (i) Consolidated Funded Indebtedness as of such date minus (ii) Unrestricted Cash as of such date to (b) Consolidated EBITDA (each as defined in the Credit Agreement) for the period of four fiscal quarters most recently ended on or prior to such date | ||||
Credit Facility | The Company's $1.2 billion credit facility due in September of 2026 granted under the terms of the Credit Agreement | ||||
CRS | Communication and Related Services (Divested December 2022) | ||||
DEA | U.S. Drug Enforcement Administration. The DEA is a division of the DOJ. It is the federal agency which regulates the manufacture, dispensing, storage, and shipment of controlled substances including medications with human abuse potential | ||||
DOJ | U.S. Department of Justice | ||||
Domestic Environmental Solutions | Hazardous Waste Solutions and Manufacturing and Industrial Services (Divested April 2020) | ||||
DSO | Days Sales Outstanding as reported, defined as the average number of days that it takes a company to collect payment after revenue has been recorded, computed as the trailing twelve months of Revenues for the period ended, divided by the Accounts Receivable balance at the end of the period. Days Sales Outstanding, net of Deferred Revenues is similarly computed except Accounts Receivable balance is netted with Deferred Revenues. | ||||
DTSC | U.S. Department of Toxic Substances Control | ||||
EBITDA | Earnings Before Interest, Taxes, Depreciation & Amortization. Another common financial term utilized by Stericycle to analyze the core profitability of the business before interest, tax, depreciation and amortization | ||||
Enviri | Enviri Corporation, a Delaware Corporation, formerly known as Harsco Corporation | ||||
ERP | Enterprise Resource Planning | ||||
Exchange Act | U.S. Securities Exchange Act of 1934 | ||||
FCPA | U.S. Foreign Corrupt Practices Act | ||||
FCPA Settlement | FCPA settlement with the SEC, the DOJ and Brazil authorities of approximately $90 million and engagement of an independent compliance monitor for 2 years and self-reporting for additional year | ||||
International | Operating segment including Europe, Middle East, Asia Pacific (Divested our Korea operations in June 2023, which was our last remaining Asia Pacific business) and Latin America (Divested our Brazil operations in April 2023, which was our last remaining Latin America business) Business operations outside of North America | ||||
IRS | U.S. Internal Revenue Service | ||||
LIBOR | London Interbank Offered Rate - benchmark interest rate that was replaced by SOFR | ||||
Net Debt | As defined in the Credit Agreement, adding back unamortized debt issuance costs, less cash and cash equivalents | ||||
North America | Operating segment in North America, including U.S., Canada and Puerto Rico | ||||
NOV | Notice of Violation | ||||
Other Costs | Represents corporate enabling and shared services costs, annual incentive and stock-based compensation | ||||
Purchase Agreement | Stock Purchase Agreement, dated as of February 6, 2020, by and between Stericycle, Inc., and the Harsco Corporation (now known as Enviri Corporation) and CEI Holding LLC, a Delaware limited liability company and subsidiary of Harsco Corporation (now known as Enviri Corporation) | ||||
PSU | Performance-based Restricted Stock Unit | ||||
RSU | Restricted Stock Unit | ||||
RWCS | Regulated Waste and Compliance Services, a business unit that provides regulated medical waste services | ||||
SEC | U.S. Securities and Exchange Commission | ||||
Senior Notes | 5.375% ($600.0 million) Senior Notes due July 2024 and 3.875% ($500.0 million) Senior Notes due January 2029 | ||||
SG&A | Selling, general and administrative expenses | ||||
SID | Secure Information Destruction Services, a business unit that provides confidential customer material shredding services and recycling of shredded paper | ||||
SOFR | Secured Overnight Financing Rate - benchmark interest rate that replaced LIBOR | ||||
SOP | Sorted Office Paper | ||||
SQ Settlement | Small quantity medical waste customers class action settlement of $295.0 million | ||||
Term Facility | Aggregate amount of commitments made by any lender under the terms of the Credit Agreement | ||||
Term Loans | Advances made by any lender under the Term Facility | ||||
TSA | Transition Services Agreement | ||||
UAE | United Arab Emirates | ||||
U.S. | United States of America | ||||
U.S. GAAP | U.S. Generally Accepted Accounting Principles |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 4 |
In millions, except per share data | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Revenues | $ | $ | $ | $ | |||||||||||||||||||
Cost of revenues | |||||||||||||||||||||||
Gross profit | |||||||||||||||||||||||
Selling, general and administrative expenses | |||||||||||||||||||||||
Divestiture losses, net (Note 3) | |||||||||||||||||||||||
Income from operations | |||||||||||||||||||||||
Interest expense, net | ( | ( | ( | ( | |||||||||||||||||||
Other income (expense), net | ( | ||||||||||||||||||||||
Income (loss) before income taxes | ( | ||||||||||||||||||||||
Income tax expense | ( | ( | ( | ( | |||||||||||||||||||
Net income (loss) | ( | ||||||||||||||||||||||
Net income attributable to noncontrolling interests | ( | ( | ( | ||||||||||||||||||||
Net income (loss) attributable to Stericycle, Inc. common shareholders | $ | $ | $ | ( | $ | ||||||||||||||||||
Income (loss) per common share attributable to Stericycle, Inc. common shareholders: | |||||||||||||||||||||||
Basic | $ | $ | $ | ( | $ | ||||||||||||||||||
Diluted | $ | $ | $ | ( | $ | ||||||||||||||||||
Weighted average number of common shares outstanding: | |||||||||||||||||||||||
Basic | |||||||||||||||||||||||
Diluted |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 5 |
In millions | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Net income (loss) | $ | $ | $ | ( | $ | ||||||||||||||||||
Other comprehensive (loss) income: | |||||||||||||||||||||||
Currency translation adjustments | ( | ( | ( | ( | |||||||||||||||||||
Cumulative currency translation loss realized from divestitures | |||||||||||||||||||||||
Total other comprehensive (loss) income | ( | ( | ( | ||||||||||||||||||||
Comprehensive (loss) income | ( | ( | ( | ||||||||||||||||||||
Less: comprehensive income (loss) attributable to noncontrolling interests | ( | ( | ( | ||||||||||||||||||||
Comprehensive (loss) income attributable to Stericycle, Inc. common shareholders | $ | ( | $ | ( | $ | $ | ( |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 6 |
In millions, except per share data | |||||||||||
September 30, 2023 | December 31, 2022 | ||||||||||
ASSETS | |||||||||||
Current Assets: | |||||||||||
Cash and cash equivalents | $ | $ | |||||||||
Accounts receivable, less allowance for doubtful accounts of $ | |||||||||||
Prepaid expenses | |||||||||||
Other current assets | |||||||||||
Total Current Assets | |||||||||||
Property, plant and equipment, less accumulated depreciation of $ | |||||||||||
Operating lease right-of-use assets | |||||||||||
Goodwill | |||||||||||
Intangible assets, less accumulated amortization of $ | |||||||||||
Other assets | |||||||||||
Total Assets | $ | $ | |||||||||
LIABILITIES AND EQUITY | |||||||||||
Current Liabilities: | |||||||||||
Current portion of long-term debt | $ | $ | |||||||||
Bank overdrafts | |||||||||||
Accounts payable | |||||||||||
Accrued liabilities | |||||||||||
Operating lease liabilities | |||||||||||
Deferred revenues | |||||||||||
Other current liabilities | |||||||||||
Total Current Liabilities | |||||||||||
Long-term debt, net | |||||||||||
Long-term operating lease liabilities | |||||||||||
Deferred income taxes | |||||||||||
Long-term income taxes payable | |||||||||||
Other liabilities | |||||||||||
Total Liabilities | |||||||||||
Commitments and contingencies (Note 8 - Commitments and Contingencies) | |||||||||||
EQUITY | |||||||||||
Common stock (par value $ | |||||||||||
Additional paid-in capital | |||||||||||
Retained earnings | |||||||||||
Accumulated other comprehensive loss | ( | ( | |||||||||
Total Stericycle, Inc.’s Equity | |||||||||||
Noncontrolling interests | |||||||||||
Total Equity | |||||||||||
Total Liabilities and Equity | $ | $ |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 7 |
In millions | |||||||||||
Nine Months Ended September 30, | |||||||||||
2023 | 2022 | ||||||||||
OPERATING ACTIVITIES: | |||||||||||
Net (loss) income | $ | ( | $ | ||||||||
Adjustments to reconcile net (loss) income to net cash from operating activities: | |||||||||||
Depreciation | |||||||||||
Intangible amortization | |||||||||||
Stock-based compensation expense | |||||||||||
Deferred income taxes | |||||||||||
Divestiture losses, net | |||||||||||
Asset impairments, (gain) loss on disposal of property plant and equipment and other charges | |||||||||||
Other, net | |||||||||||
Changes in operating assets and liabilities: | |||||||||||
Accounts receivable | ( | ( | |||||||||
Prepaid expenses | ( | ||||||||||
Accounts payable | ( | ( | |||||||||
Accrued liabilities | ( | ( | |||||||||
Deferred revenues | ( | ||||||||||
Other assets and liabilities | ( | ( | |||||||||
Net cash from operating activities | |||||||||||
INVESTING ACTIVITIES: | |||||||||||
Capital expenditures | ( | ( | |||||||||
Proceeds from divestiture of businesses, net | |||||||||||
Other, net | |||||||||||
Net cash from investing activities | ( | ( | |||||||||
FINANCING ACTIVITIES: | |||||||||||
Repayments of long-term debt and other obligations | ( | ( | |||||||||
Proceeds from foreign bank debt | |||||||||||
Repayments of foreign bank debt | ( | ( | |||||||||
Repayments of term loan | ( | ||||||||||
Proceeds from credit facility | |||||||||||
Repayments of credit facility | ( | ( | |||||||||
(Repayments) proceeds of bank overdrafts, net | ( | ||||||||||
Payments of finance lease obligations | ( | ( | |||||||||
Payments of debt issuance costs | ( | ||||||||||
Proceeds from issuance of common stock, net of (payments of) taxes from withheld shares | ( | ( | |||||||||
Payments to noncontrolling interest | ( | ( | |||||||||
Net cash from financing activities | ( | ||||||||||
Effect of exchange rate changes on cash and cash equivalents | ( | ||||||||||
Net change in cash and cash equivalents | ( | ( | |||||||||
Cash and cash equivalents at beginning of period | |||||||||||
Cash and cash equivalents at end of period | $ | $ | |||||||||
SUPPLEMENTAL CASH FLOW INFORMATION: | |||||||||||
Interest paid, net of capitalized interest | $ | $ | |||||||||
Income taxes paid, net | $ | $ | |||||||||
Capital expenditures in Accounts payable | $ | $ |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 8 |
In millions | |||||||||||||||||||||||||||||||||||||||||
Stericycle, Inc. Equity | |||||||||||||||||||||||||||||||||||||||||
Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive (Loss) Income | Noncontrolling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||||||||||||||
Balance as of July 1, 2023 | $ | $ | $ | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||
Net income | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Currency translation adjustment | — | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||||
Cumulative currency translation loss realized from divestitures | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Changes in noncontrolling interest | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Balance as of September 30, 2023 | $ | $ | $ | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||
In millions | |||||||||||||||||||||||||||||||||||||||||
Stericycle, Inc. Equity | |||||||||||||||||||||||||||||||||||||||||
Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive (Loss) Income | Noncontrolling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||||||||||||||
Balance as of July 1, 2022 | $ | $ | $ | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||
Net income | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Currency translation adjustment | — | — | — | — | ( | ( | ( | ||||||||||||||||||||||||||||||||||
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Changes in noncontrolling interest | — | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||||
Balance as of September 30, 2022 | $ | $ | $ | $ | ( | $ | $ |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 9 |
In millions | |||||||||||||||||||||||||||||||||||||||||
Stericycle, Inc. Equity | |||||||||||||||||||||||||||||||||||||||||
Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive (Loss) Income | Noncontrolling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2022 | $ | $ | $ | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||
Net (loss) income | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||
Currency translation adjustment | — | — | — | — | ( | ( | ( | ||||||||||||||||||||||||||||||||||
Cumulative currency translation loss realized from divestitures | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares | — | ( | — | — | — | ( | |||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Changes in noncontrolling interest | — | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||||
Balance as of September 30, 2023 | $ | $ | $ | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||
In millions | |||||||||||||||||||||||||||||||||||||||||
Stericycle, Inc. Equity | |||||||||||||||||||||||||||||||||||||||||
Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Noncontrolling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2021 | $ | $ | $ | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||
Net income | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Currency translation adjustment | — | — | — | — | ( | ( | ( | ||||||||||||||||||||||||||||||||||
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares | — | ( | — | — | — | ( | |||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Changes in noncontrolling interest | — | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||||
Balance as of September 30, 2022 | $ | $ | $ | $ | ( | $ | $ |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 10 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 11 |
In millions | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Revenue by Service | |||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | $ | $ | $ | |||||||||||||||||||
Secure Information Destruction Services | |||||||||||||||||||||||
Total Revenues | $ | $ | $ | $ | |||||||||||||||||||
North America | |||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | $ | $ | $ | |||||||||||||||||||
Secure Information Destruction Services | |||||||||||||||||||||||
Total North America Segment | $ | $ | $ | $ | |||||||||||||||||||
International | |||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | $ | $ | $ | |||||||||||||||||||
Secure Information Destruction Services | |||||||||||||||||||||||
Total International Segment | $ | $ | $ | $ |
In millions | |||||||||||
September 30, 2023 | December 31, 2022 | ||||||||||
Other current assets | $ | $ | |||||||||
Other assets | |||||||||||
Total contract acquisition costs | $ | $ |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 12 |
In millions | |||||||||||
Nine Months Ended September 30, | |||||||||||
2023 | 2022 | ||||||||||
Beginning Balance | $ | $ | |||||||||
Bad debt expense, net of recoveries | |||||||||||
Write-offs | ( | ( | |||||||||
Other changes(1) | ( | ( | |||||||||
Ending Balance | $ | $ |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 13 |
In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2023 | ||||||||||||||||||||||||||||||||||
Loss - pre-cumulative currency translation | Cumulative currency translation loss realized | Total loss | Loss (gain) - pre-cumulative currency translation | Cumulative currency translation loss (gain) realized | Total loss (gain) | ||||||||||||||||||||||||||||||
Divestitures | |||||||||||||||||||||||||||||||||||
International Segment | |||||||||||||||||||||||||||||||||||
Romania Operations | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
UAE Joint Venture | |||||||||||||||||||||||||||||||||||
Netherlands Dental Operations | |||||||||||||||||||||||||||||||||||
Republic of Korea Operations | ( | ( | ( | ||||||||||||||||||||||||||||||||
Australia and Singapore Operations | |||||||||||||||||||||||||||||||||||
Brazil Operations | |||||||||||||||||||||||||||||||||||
International Container Manufacturing Operations | |||||||||||||||||||||||||||||||||||
Divestiture losses (gains), net | $ | $ | $ | $ | ( | $ | $ | ||||||||||||||||||||||||||||
In millions | |||||||||||
September 30, 2023 | December 31, 2022 | ||||||||||
$ | $ | $ | |||||||||
$ | |||||||||||
$ | |||||||||||
$ | |||||||||||
Promissory notes and deferred consideration weighted average maturity of | |||||||||||
Foreign bank debt weighted average maturity | |||||||||||
Obligations under finance leases | |||||||||||
Total debt | |||||||||||
Less: current portion of total debt | |||||||||||
Less: unamortized debt issuance costs | |||||||||||
Long-term portion of total debt | $ | $ |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 14 |
Nine Months Ended September 30, 2023 | Year Ended December 31, 2022 | ||||||||||
$ | % | % | |||||||||
$ | % | % | |||||||||
$ | % | % | |||||||||
$ | % | % | |||||||||
Promissory notes and deferred consideration (fixed rate) | % | % | |||||||||
Foreign bank debt (fixed rate) | N/A | % |
In millions | |||||||||||
September 30, 2023 | December 31, 2022 | ||||||||||
Outstanding letters of credit under Credit Facility | $ | $ | |||||||||
Unused portion of the Credit Facility |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 15 |
In millions of shares | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Weighted average common shares outstanding - basic | |||||||||||||||||||||||
Incremental shares outstanding related to stock-based awards (1) | |||||||||||||||||||||||
Weighted average common shares outstanding - diluted |
In thousands of shares | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Option awards | |||||||||||||||||||||||
RSU awards |
In millions | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Adjusted Income from Operations | |||||||||||||||||||||||
North America | $ | $ | $ | $ | |||||||||||||||||||
International | |||||||||||||||||||||||
Other Costs | ( | ( | ( | ( | |||||||||||||||||||
Total Adjusted Income from Operations | $ | $ | $ | $ | |||||||||||||||||||
2023 Q3 10-Q Report | Stericycle, Inc. ● | 16 |
In millions | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Total Reportable Segment Adjusted Income from Operations | $ | $ | $ | $ | |||||||||||||||||||
Adjusting Items: | |||||||||||||||||||||||
ERP and System Modernization | ( | ( | ( | ( | |||||||||||||||||||
Intangible Amortization | ( | ( | ( | ( | |||||||||||||||||||
Portfolio Optimization | ( | ( | ( | ( | |||||||||||||||||||
Litigation, Settlements and Regulatory Compliance | ( | ( | ( | ( | |||||||||||||||||||
Asset Impairments | ( | ( | ( | ( | |||||||||||||||||||
Income from operations | $ | $ | $ | $ |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 17 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 18 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 19 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 20 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 21 |
In millions | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Pre-tax items: | |||||||||||||||||||||||
Included in COR | |||||||||||||||||||||||
Asset Impairments | $ | — | $ | — | $ | 3.4 | $ | — | |||||||||||||||
Total included in COR | — | — | 3.4 | — | |||||||||||||||||||
Included in SG&A | |||||||||||||||||||||||
ERP and System Modernization | 4.8 | 3.9 | 12.9 | 13.0 | |||||||||||||||||||
Intangible Amortization | 27.9 | 31.5 | 84.2 | 94.7 | |||||||||||||||||||
Portfolio Optimization | 0.8 | 1.4 | 1.4 | 2.7 | |||||||||||||||||||
Litigation, Settlements and Regulatory Compliance | 5.3 | 2.6 | 22.4 | 26.0 | |||||||||||||||||||
Asset Impairments | 3.1 | 2.0 | 3.1 | 2.0 | |||||||||||||||||||
Total included in SG&A | 41.9 | 41.4 | 124.0 | 138.4 | |||||||||||||||||||
Divestiture losses, net | 4.2 | — | 63.4 | — | |||||||||||||||||||
Total included in Income from operations | $ | 46.1 | $ | 41.4 | $ | 190.8 | $ | 138.4 | |||||||||||||||
In millions | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
North America | |||||||||||||||||||||||
Operating expenditures | $ | 3.6 | $ | 3.9 | $ | 11.3 | $ | 13.0 | |||||||||||||||
Capital expenditures | 5.6 | 5.0 | 14.3 | 9.1 | |||||||||||||||||||
Total North America | $ | 9.2 | $ | 8.9 | $ | 25.6 | $ | 22.1 | |||||||||||||||
International | |||||||||||||||||||||||
Operating expenditures | $ | 1.2 | $ | — | $ | 1.6 | $ | — | |||||||||||||||
Capital expenditures | — | — | — | — | |||||||||||||||||||
Total International | $ | 1.2 | $ | — | $ | 1.6 | $ | — | |||||||||||||||
Total operating expenditures | $ | 4.8 | $ | 3.9 | $ | 12.9 | $ | 13.0 | |||||||||||||||
Total capital expenditures | 5.6 | 5.0 | 14.3 | 9.1 | |||||||||||||||||||
Total ERP and System Modernization | $ | 10.4 | $ | 8.9 | $ | 27.2 | $ | 22.1 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 22 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 23 |
Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||||||||
In millions | Components of Change (%)(1) | ||||||||||||||||||||||||||||||||||||||||
2023 | 2022 | Change ($) | Change (%) | Organic Growth(2) | Divestitures | Foreign Exchange(3) | |||||||||||||||||||||||||||||||||||
Revenue by Service | |||||||||||||||||||||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | 439.9 | $ | 447.8 | $ | (7.9) | (1.8) | % | 4.1 | % | (6.7) | % | 1.1 | % | |||||||||||||||||||||||||||
Secure Information Destruction Services | 213.6 | 242.5 | (28.9) | (11.9) | % | (11.6) | % | (1.0) | % | 0.5 | % | ||||||||||||||||||||||||||||||
Total Revenues | $ | 653.5 | $ | 690.3 | $ | (36.8) | (5.3) | % | (1.6) | % | (4.7) | % | 0.9 | % | |||||||||||||||||||||||||||
North America | |||||||||||||||||||||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | 368.0 | $ | 369.7 | $ | (1.7) | (0.5) | % | 3.9 | % | (4.1) | % | (0.1) | % | |||||||||||||||||||||||||||
Secure Information Destruction Services | 189.1 | 215.1 | (26.0) | (12.1) | % | (11.9) | % | — | % | (0.2) | % | ||||||||||||||||||||||||||||||
Total North America Segment | $ | 557.1 | $ | 584.8 | $ | (27.7) | (4.7) | % | (2.1) | % | (2.6) | % | (0.1) | % | |||||||||||||||||||||||||||
International | |||||||||||||||||||||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | 71.9 | $ | 78.1 | $ | (6.2) | (7.9) | % | 5.4 | % | (18.9) | % | 6.6 | % | |||||||||||||||||||||||||||
Secure Information Destruction Services | 24.5 | 27.4 | (2.9) | (10.6) | % | (9.2) | % | (8.7) | % | 6.4 | % | ||||||||||||||||||||||||||||||
Total International Segment | $ | 96.4 | $ | 105.5 | $ | (9.1) | (8.6) | % | 1.3 | % | (16.2) | % | 6.6 | % | |||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||||||||
In millions | Components of Change (%)(1) | ||||||||||||||||||||||||||||||||||||||||
2023 | 2022 | Change ($) | Change (%) | Organic Growth(2) | Divestitures | Foreign Exchange(3) | |||||||||||||||||||||||||||||||||||
Revenue by Service | |||||||||||||||||||||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | 1,335.9 | $ | 1,348.9 | $ | (13.0) | (1.0) | % | 4.6 | % | (5.2) | % | (0.2) | % | |||||||||||||||||||||||||||
Secure Information Destruction Services | 671.4 | 685.5 | (14.1) | (2.1) | % | (1.1) | % | (0.5) | % | (0.5) | % | ||||||||||||||||||||||||||||||
Total Revenues | $ | 2,007.3 | $ | 2,034.4 | $ | (27.1) | (1.3) | % | 2.6 | % | (3.6) | % | (0.3) | % | |||||||||||||||||||||||||||
North America | |||||||||||||||||||||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | 1,103.1 | $ | 1,097.5 | $ | 5.6 | 0.5 | % | 5.0 | % | (4.1) | % | (0.2) | % | |||||||||||||||||||||||||||
Secure Information Destruction Services | 592.6 | 599.7 | (7.1) | (1.2) | % | (0.7) | % | — | % | (0.4) | % | ||||||||||||||||||||||||||||||
Total North America Segment | $ | 1,695.7 | $ | 1,697.2 | $ | (1.5) | (0.1) | % | 2.9 | % | (2.7) | % | (0.3) | % | |||||||||||||||||||||||||||
International | |||||||||||||||||||||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | 232.8 | $ | 251.4 | $ | (18.6) | (7.4) | % | 2.5 | % | (9.7) | % | — | % | |||||||||||||||||||||||||||
Secure Information Destruction Services | 78.8 | 85.8 | (7.0) | (8.2) | % | (3.8) | % | (3.9) | % | (0.6) | % | ||||||||||||||||||||||||||||||
Total International Segment | $ | 311.6 | $ | 337.2 | $ | (25.6) | (7.6) | % | 0.8 | % | (8.2) | % | (0.2) | % |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 24 |
In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Gross profit | 245.7 | 37.6 | % | 266.2 | 38.6 | % | (20.5) | (7.7) | % | ||||||||||||||||||||||||||
In millions | |||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Gross profit | 757.8 | 37.8 | % | 771.1 | 37.9 | % | (13.3) | (1.7) | % |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 25 |
In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
SG&A | 217.3 | 33.3 | % | 215.6 | 31.2 | % | 1.7 | 0.8 | % | ||||||||||||||||||||||||||
In millions | |||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
SG&A | 654.2 | 32.6 | % | 676.5 | 33.3 | % | (22.3) | (3.3) | % |
In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Divestiture losses, net | 4.2 | 0.6 | % | — | — | % | 4.2 | nm | |||||||||||||||||||||||||||
In millions | |||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Divestiture losses, net | 63.4 | 3.2 | % | — | — | % | 63.4 | nm |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 26 |
In millions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2023 | 2022 | Change 2023 versus 2022 | 2023 | 2022 | Change 2023 versus 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
$ | % Segment Revenues | $ | % Segment Revenues | $ | % | $ | % Segment Revenues | $ | % Segment Revenues | $ | % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adjusted Income from Operations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
North America | 143.5 | 25.8 | % | 160.4 | 27.4 | % | (16.9) | (10.5) | % | 460.3 | 27.1 | % | 443.9 | 26.2 | % | 16.4 | 3.7 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||
International | 8.9 | 9.2 | % | 7.4 | 7.0 | % | 1.5 | 20.3 | % | 27.6 | 8.9 | % | 27.2 | 8.1 | % | 0.4 | 1.5 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Costs | (82.1) | nm | (75.8) | nm | (6.3) | (8.3) | % | (256.9) | nm | (238.1) | nm | (18.8) | (7.9) | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 70.3 | 10.8 | % | 92.0 | 13.3 | % | (21.7) | (23.6) | % | 231.0 | 11.5 | % | 233.0 | 11.5 | % | (2.0) | (0.9) | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation to Income from operations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adjusted Income from Operations | 70.3 | 92.0 | 231.0 | 233.0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adjusting Items Total (1) | (46.1) | (41.4) | (190.8) | (138.4) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income from operations | 24.2 | 50.6 | 40.2 | 94.6 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 27 |
In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Interest expense, net | 17.4 | 2.7 | % | 19.8 | 2.9 | % | (2.4) | (12.1) | % | ||||||||||||||||||||||||||
In millions | |||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Interest expense, net | 56.9 | 2.8 | % | 54.6 | 2.7 | % | 2.3 | 4.2 | % |
In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Other income (expense), net | 0.1 | — | % | 2.3 | 0.3 | % | (2.2) | (95.7) | % | ||||||||||||||||||||||||||
In millions | |||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Other income (expense), net | (0.3) | — | % | 0.8 | — | % | (1.1) | (137.5) | % |
In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | Effective Rate | $ | Effective Rate | $ | % | ||||||||||||||||||||||||||||||
Income tax expense | 4.8 | 69.6 | % | 5.1 | 15.4 | % | (0.3) | (5.9) | % | ||||||||||||||||||||||||||
In millions | |||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||
2023 | 2022 | Change | |||||||||||||||||||||||||||||||||
$ | Effective Rate | $ | Effective Rate | $ | % | ||||||||||||||||||||||||||||||
Income tax expense | 19.1 | (112.4) | % | 16.4 | 40.2 | % | 2.7 | 16.5 | % |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 28 |
In millions | |||||||||||
Nine Months Ended September 30, | |||||||||||
2023 | 2022 | ||||||||||
Net cash from operating activities | $ | 193.3 | $ | 43.1 | |||||||
Net cash from investing activities | (15.5) | (103.5) | |||||||||
Net cash from financing activities | (205.2) | 56.7 | |||||||||
Effect of exchange rate changes on cash and cash equivalents | 1.1 | (7.9) | |||||||||
Net change in cash and cash equivalents | $ | (26.3) | $ | (11.6) |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 29 |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 30 |
PART II – OTHER INFORMATION |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 31 |
Exhibit Index | Description | |||||||
3.1 | ||||||||
3.2 | ||||||||
3.3 | ||||||||
3.4 | ||||||||
3.5 | ||||||||
3.6 | ||||||||
3.7 | ||||||||
3.8 | ||||||||
3.9 | ||||||||
3.10 | ||||||||
10.1 | ||||||||
31.1 | ||||||||
31.2 | ||||||||
32 | ||||||||
101 | The following information from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline XBRL: (i) Condensed Consolidated Statements of Income (Loss); (ii) Condensed Consolidated Statements of Comprehensive (Loss) Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Cash Flows; (v) Condensed Consolidated Statements of Changes in Equity; (vi) Notes to Condensed Consolidated Financial Statements, and (vii) the information under Part II, Item 5, “Other Information” | |||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 32 |
STERICYCLE, INC. | |||||
(Registrant) | |||||
By: /s/ JANET H. ZELENKA | |||||
Janet H. Zelenka | |||||
Executive Vice President, Chief Financial Officer & Chief Information Officer |
2023 Q3 10-Q Report | Stericycle, Inc. ● | 33 |
US.134317657.03 |
US.134317657.03 |
US.134317657.03 |
US.134317657.03 |
US.134317657.03 |
US.134317657.03 |
US.134317657.03 |
US.134317657.03 |
US.134317657.03 |
US.134317657.03 |
/s/ CINDY J. MILLER | ||||||||
Cindy J. Miller | ||||||||
Chief Executive Officer | ||||||||
Stericycle, Inc. |
/s/ JANET H. ZELENKA | ||||||||
Janet H. Zelenka | ||||||||
Executive Vice President, Chief Financial Officer & Chief Information Officer | ||||||||
Stericycle, Inc. |
/s/ CINDY J. MILLER | ||||||||
Cindy J. Miller | ||||||||
Chief Executive Officer | ||||||||
Stericycle, Inc. |
/s/ JANET H. ZELENKA | ||||||||
Janet H. Zelenka | ||||||||
Executive Vice President, Chief Financial Officer & Chief Information Officer | ||||||||
Stericycle, Inc. |
-M3B%RQ1@^YYN%Y0=B,!!K7SC&;KW(M*9ZO^C+5C[
M54W&*3"GSMYM:0H3,"]4]ORY!O,EWUON[IVPOJ71V ==>%0Q)F T[27(EFGU
MX6<0*/P]5Y)S GK'8&/K&04A@Q1 1[SGZ(P@.K(5!?\.
M-2E&Y8LB$%33&]16D F^24 &@97$%GB953FJ.V^K%\(&XC[/I&B# %-2LIC3
MP/LLQ$?V64\TFF2\Z]5G5P/!VVZBZ(/MV3&-. 04!&D1
MH0>K,K$!21*&V!T)(G1DE]SA(F1TG_[P>>USI/U>IM,%^>@'?5DD6MO5E%[U
M3LUJ2J2*H'&6 MF7]S0 I?<9,-V.+N$/.OO ,@4;)2+_765!4,A?35TX&LJ
M>
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (Unaudited) - USD ($) shares in Millions, $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
Income Statement [Abstract] | ||||
Revenues | $ 653.5 | $ 690.3 | $ 2,007.3 | $ 2,034.4 |
Cost of revenues | 407.8 | 424.1 | 1,249.5 | 1,263.3 |
Gross profit | 245.7 | 266.2 | 757.8 | 771.1 |
Selling, general and administrative expenses | 217.3 | 215.6 | 654.2 | 676.5 |
Divestiture losses, net | 4.2 | 0.0 | 63.4 | 0.0 |
Income from operations | 24.2 | 50.6 | 40.2 | 94.6 |
Interest expense, net | (17.4) | (19.8) | (56.9) | (54.6) |
Other income (expense), net | 0.1 | 2.3 | (0.3) | 0.8 |
Income (loss) before income taxes | 6.9 | 33.1 | (17.0) | 40.8 |
Income tax expense | (4.8) | (5.1) | (19.1) | (16.4) |
Net income (loss) | 2.1 | 28.0 | (36.1) | 24.4 |
Net income attributable to noncontrolling interests | (0.1) | 0.0 | (0.2) | (0.2) |
Net income (loss) attributable to Stericycle, Inc. common shareholders | $ 2.0 | $ 28.0 | $ (36.3) | $ 24.2 |
Income (loss) per common share attributable to Stericycle, Inc. common shareholders: | ||||
Basic (in dollars per share) | $ 0.02 | $ 0.30 | $ (0.39) | $ 0.26 |
Diluted (in dollars per share) | $ 0.02 | $ 0.30 | $ (0.39) | $ 0.26 |
Weighted average number of common shares outstanding: | ||||
Basic (in shares) | 92.5 | 92.2 | 92.4 | 92.1 |
Diluted (in shares) | 92.9 | 92.4 | 92.4 | 92.4 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
Statement of Comprehensive Income [Abstract] | ||||
Net income (loss) | $ 2.1 | $ 28.0 | $ (36.1) | $ 24.4 |
Other comprehensive (loss) income: | ||||
Currency translation adjustments | (21.8) | (65.4) | (7.8) | (120.3) |
Cumulative currency translation loss realized from divestitures | 1.0 | 0.0 | 70.6 | 0.0 |
Total other comprehensive (loss) income | (20.8) | (65.4) | 62.8 | (120.3) |
Comprehensive (loss) income | (18.7) | (37.4) | 26.7 | (95.9) |
Less: comprehensive income (loss) attributable to noncontrolling interests | 0.1 | (0.3) | (2.1) | (0.6) |
Comprehensive (loss) income attributable to Stericycle, Inc. common shareholders | $ (18.8) | $ (37.1) | $ 28.8 | $ (95.3) |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Millions |
Sep. 30, 2023 |
Dec. 31, 2022 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts | $ 47.1 | $ 53.3 |
Property, plant and equipment, accumulated depreciation | 665.3 | 657.7 |
Intangible assets, accumulated amortization | $ 889.2 | $ 823.3 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, authorized (in shares) | 120,000,000.0 | 120,000,000.0 |
Common stock, issued (in shares) | 92,500,000 | 92,200,000 |
Common stock, outstanding (in shares) | 92,500,000 | 92,200,000 |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
9 Months Ended |
---|---|
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Summary of Significant Accounting Policies Basis of Presentation: The accompanying unaudited condensed consolidated financial statements include the accounts of Stericycle, Inc. and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company's condensed consolidated financial statements were prepared in accordance with U.S. GAAP and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries and majority-owned subsidiaries over which the Company exercises control. Outside stockholders' interests in subsidiaries are shown on the condensed consolidated financial statements as “Noncontrolling interests”. The accompanying unaudited condensed consolidated financial statements as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022, have been prepared pursuant to the rules and regulations of the SEC for interim reporting and, therefore, do not include all information and footnote disclosures normally included in audited financial statements prepared in conformity with U.S. GAAP. In the opinion of management, however, all adjustments, consisting of normal recurring adjustments necessary to present fairly the results of operations, financial position and cash flows have been made. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the 2022 Form 10-K. The results of operations for any interim period are not necessarily indicative of the results of operations to be expected for the full year or any other period. Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Some areas where the Company makes estimates include allowance for doubtful accounts, credit memo reserves, contingent liabilities, asset retirement obligations, stock compensation expense, income tax assets and liabilities, accrued employee health and welfare benefits, accrued auto and workers’ compensation self-insured claims, leases, goodwill and held for sale impairment valuations. Such estimates are based on historical trends and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates.
|
REVENUES FROM CONTRACTS WITH CUSTOMERS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REVENUES FROM CONTRACTS WITH CUSTOMERS | REVENUES FROM CONTRACTS WITH CUSTOMERS The Company provides RWCS, which provide collection and processing of regulated and specialized waste, including medical, pharmaceutical and hazardous waste, for disposal and compliance programs and SID services, which provide for the collection of personal and confidential information for secure destruction and recycling of shredded paper. The Company’s customers typically enter into a contract for the provision of services on a regular and scheduled basis, e.g., weekly, monthly or on an as needed basis over the contract term, e.g., one-time service. Under the contract terms, the Company receives fees based on a monthly, quarterly or annual rate and/or fees based on contractual rates depending upon measures including the volume, weight, and type of waste, number and size of containers collected, and weight and type of shredded paper. Amounts are invoiced based on the terms of the underlying contract either on a regular basis, e.g., monthly or quarterly, or as services are performed and are generally due within a short period of time after invoicing based upon normal terms and conditions for our business type and the geography of the services performed. Disaggregation of Revenue The following table presents revenues disaggregated by service and reportable segments:
Deferred Revenues Deferred revenues are recognized when cash payments are received or when the Company bills for services in advance of performance. Deferred revenues as of September 30, 2023 and December 31, 2022, were $65.1 million and $7.9 million, respectively. Beginning in the third quarter of 2023, the Company advanced billings for certain Regulated Waste services. Deferred revenues are classified within current liabilities since the revenues are earned within 12 months and there are no significant financing components. Contract Acquisition Costs The Company’s incremental direct costs of obtaining a contract, which consist primarily of sales incentives, are deferred and amortized to SG&A over a weighted average estimated period of benefit of 6.5 years. During the three months ended September 30, 2023 and 2022, the Company amortized $4.2 million and $3.8 million, respectively, of deferred sales incentives to SG&A. During the nine months ended September 30, 2023 and 2022, the Company amortized $12.3 million and $10.8 million, respectively, of deferred sales incentives to SG&A. Total contract acquisition costs, net of accumulated amortization, were classified as follows:
Allowance for Doubtful Accounts The Company estimates its allowance for doubtful accounts based on past collection history and specific risks identified among uncollected amounts, as well as management’s expectation of future economic conditions. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Past-due receivable balances are written off when the Company’s collection efforts have been exhausted. The changes in allowance for doubtful accounts were reported as follows:
|
RESTRUCTURING, DIVESTITURES, AND ASSET IMPAIRMENTS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RESTRUCTURING, DIVESTITURES, AND ASSET IMPAIRMENTS | RESTRUCTURING, DIVESTITURES, AND ASSET IMPAIRMENTS Restructuring – Operational Optimization: In October 2023, the Company recognized Operational Optimization charges of approximately $3.0 million, split between its North America and International segments, related to headcount reduction. North America Divestiture On December 1, 2022, the Company completed the sale of its Communication Solutions business for cash proceeds of approximately $45.0 million. The transaction resulted in a pre-tax gain of $15.6 million in the fourth quarter of 2022. In connection with the transaction, the Company entered into certain additional ancillary agreements including a TSA, for up to 12 months. The Company allocated and deferred $1.4 million of the proceeds, which will be recognized over the duration of the TSA period offsetting the expenses incurred to deliver TSA services not reimbursed by the buyer. International Divestitures On October 6, 2023, the Company exited its operations in Romania for nominal consideration which resulted in a third-quarter assets-held-for-sale impairment charges of $4.2 million, of which $1.0 million relates to the reclassification of non-cash accumulated currency translation adjustments to earnings. The impairment charge is included in Divestiture losses, net in the Condensed Consolidated Statements of Income (Loss). On July 25, 2023 and August 10, 2023, respectively, the Company exited its dental recycling business in the Netherlands and its SID joint venture in the UAE for nominal consideration which resulted in second quarter pre-tax charges of $1.5 million. On June 1, 2023, the Company exited its operations in the Republic of Korea, for cash proceeds of approximately $109.3 million. The transaction resulted in a second quarter divestiture pre-tax gain of $50.8 million, of which $2.7 million of gain related to the reclassification of non-cash accumulated currency translation adjustments to earnings. On May 24, 2023, the Company exited its operations in Australia and Singapore, for cash proceeds of approximately $2.9 million. The transaction resulted in a second quarter divestiture pre-tax loss of $7.3 million, of which $2.2 million of loss related to the reclassification of non-cash accumulated currency translation adjustments to earnings. On April 20, 2023, the Company exited its operations in Brazil for cash consideration to the acquirer of approximately $28 million. The transaction resulted in a second quarter divestiture pre-tax loss of $96.2 million, of which $70.1 million of loss related to the reclassification of non-cash accumulated currency translation adjustments to earnings. In connection with the agreement, the Company entered into a TSA with the acquirer for a period of up to six months. The agreement provides for indemnifications to the acquirer against certain liabilities. On January 19, 2023, the Company exited its International container manufacturing operations, for cash proceeds of approximately $2.2 million. The transaction resulted in a first quarter divestiture pre-tax loss of $5.0 million. In connection with the transaction, the Company entered into certain additional ancillary agreements, including an exclusive two-year supply agreement for containers. Stericycle recognized the following International pre-tax Divestiture losses (gains), net in the Condensed Consolidated Statements of Income (Loss):
Revenues of the completed divestiture transactions in 2023, each individually contributed less than 1% or in aggregate approximately 3.5% of consolidated revenues in the year ended December 31, 2022. Asset Impairments In the three and nine months ended September 30, 2023, the Company recognized an impairment in SG&A of $3.1 million in International associated with certain intangible assets in Spain. In the nine months ended September 30, 2023, the Company recognized an impairment in COR of $3.4 million in International associated with certain long-lived assets, primarily property, plant and equipment in Romania. In the three and nine months ended September 30, 2022, the Company recognized an impairment in SG&A of $2.0 million associated with exiting certain North American office facilities.
|
DEBT |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DEBT | DEBT The Company’s long-term debt consisted of the following:
The estimated fair value of our debt approximated $1.2 billion and $1.4 billion as of September 30, 2023 and December 31, 2022, respectively. These fair value amounts were estimated using an income approach by applying market interest rates for comparable instruments and developed based on inputs classified as Level 2. The weighted average interest rates on long-term debt, excluding finance leases were as follows:
The Credit Agreement contains, among other covenants, a financial covenant requiring maintenance of a maximum Credit Agreement defined Debt Leverage Ratio of 4.00 to 1.00 for any fiscal quarter ending on or after September 30, 2022, which includes, among other provisions, $50.0 million cash add backs to EBITDA with respect to any four fiscal quarter period ending on or before December 31, 2023. As of September 30, 2023, the Company was in compliance with its financial covenants. The Credit Agreement Defined Debt Leverage Ratio was 2.84 to 1.00, which was below the allowed maximum ratio of 4.00 to 1.00 as set forth in the amended Credit Agreement. If the Company's 2024 Senior Notes are still outstanding 91 days prior to their respective maturity date (the “Springing Maturity Date”), then the Credit Agreement maturity date will be the Springing Maturity Date. The Company currently has the ability and intent to refinance the 2024 Senior Notes on a long-term basis through available capacity under its Revolving Credit Facility. Therefore, as of September 30, 2023, the 2024 Senior Notes remain classified as Long-Term Debt in the Condensed Consolidated Financial Statements. Second Amendment On June 15, 2023, we entered into a Second Amendment to the Credit Agreement. Among other provisions, the Second Amendment modifies the pricing reference from the Eurocurrency Rate Loans (LIBOR) to Term SOFR Loans as defined in the Credit Agreement and allows for higher capital leases now capped at $200 million in the aggregate. Amounts committed to outstanding letters of credit and the unused portion of the Company's Senior Credit Facility were as follows:
|
INCOME TAXES |
9 Months Ended |
---|---|
Sep. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES The Company reported income tax expense of $4.8 million and $5.1 million for the three months ended September 30, 2023 and 2022, respectively. The effective tax rates for the three months ended September 30, 2023 and 2022 were 69.6% and 15.4%, respectively. The effective tax rate for the three months ended September 30, 2023 reflects (i) losses in jurisdictions that are not eligible for tax benefits on account of valuation allowances, (ii) the impact from net non-deductible losses from divestitures, and (iii) equity-based compensation awards expiring without a tax benefit, partially offset by (iv) the tax benefit associated with the U.S. federal research and development tax credit. The effective tax rate for the three months ended September 30, 2022, reflects (i) the tax benefit from the release of uncertain tax position reserves and (ii) the tax benefit associated with the U.S. federal research and development tax credit, partially offset by (iii) losses in jurisdictions that are not eligible for tax benefits on account of valuation allowances, and (iv) equity-based compensation awards expiring without a tax benefit. The Company reported income tax expense of $19.1 million and $16.4 million for the nine months ended September 30, 2023 and 2022, respectively. The effective tax rates for the nine months ended September 30, 2023 and 2022 were (112.4)% and 40.2%, respectively. The effective tax rate for the nine months ended September 30, 2023 reflects a loss from operations before tax and additionally (i) the impact from net non-deductible losses from divestitures, (ii) losses in jurisdictions that are not eligible for tax benefits on account of valuation allowances, and (iii) equity-based compensation awards expiring without a tax benefit. The effective tax rate for the nine months ended September 30, 2022 reflects (i) losses in jurisdictions that are not eligible for tax benefits on account of valuation allowances, and (ii) equity-based compensation awards expiring without a tax benefit, partially offset by (iii) the tax benefit from the release of uncertain tax position reserves.
|
EARNINGS (LOSS) PER COMMON SHARE |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EARNINGS (LOSS) PER COMMON SHARE | EARNINGS (LOSS) PER COMMON SHARE Basic earnings (loss) per share is computed by dividing Net income (loss) by the number of weighted average common shares outstanding during the reporting period. Diluted earnings (loss) per share is calculated to give effect to all potentially dilutive common shares that were outstanding during the reporting period, only in the periods in which such effect is dilutive. The following table shows the effect of stock-based awards on the weighted average number of shares outstanding used in calculating diluted earnings (loss) per share:
(1)In periods of net loss, stock-based awards are anti-dilutive and therefore excluded from the loss per share calculation. Anti-dilutive stock-based awards excluded from the computation of diluted earnings (loss) per share using the treasury stock method include the following:
PSUs are offered to key employees and are subject to achievement of specified performance conditions. Contingently issuable shares are excluded from the computation of diluted earnings (loss) per share based on current period results. The shares would not be issuable if the end of the quarter were the end of the contingency period. If such goals are not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed.
|
SEGMENT REPORTING |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SEGMENT REPORTING | SEGMENT REPORTING The Company evaluates, oversees, and manages the financial performance of two operating and reportable segments – North America and International. The following tables show financial information for the Company's reportable segments (see Note 2 – Revenues from Contracts with Customers for segment revenues):
The following table reconciles the Company's primary measure of segment profitability, Adjusted Income from Operations, to Income from operations:
|
COMMITMENTS AND CONTINGENCIES |
9 Months Ended |
---|---|
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Legal Proceedings The Company operates in highly regulated industries and responds to regulatory inquiries or investigations from time to time that may be initiated for a variety of reasons. At any given time, the Company has matters at various stages of resolution with the applicable government authorities. The Company is also routinely involved in actual or threatened legal actions, including those involving alleged personal injuries and commercial, employment, environmental, tax, and other issues. The outcomes of these matters are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, claimants seek damages, as well as other relief, including injunctive relief, that could require significant expenditures or result in lost revenue. In accordance with applicable accounting standards, the Company establishes an accrued liability for loss contingencies related to legal and regulatory matters when the loss is both probable and reasonably estimable. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is not probable or a probable loss is not reasonably estimable, no liability is recorded. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. These accruals represent management’s best estimate of probable losses and, in such cases, there may be an exposure to loss in excess of the amounts accrued. Estimates of probable losses resulting from litigation and regulatory proceedings are difficult to predict. Legal and regulatory matters inherently involve significant uncertainties based on, among other factors, the jurisdiction and stage of the proceedings, developments in the applicable facts or law, and the unpredictability of the ultimate determination of the merits of any claim, any defenses the Company may assert against that claim, and the amount of any damages that may be awarded. The Company’s accrued liabilities for loss contingencies related to legal and regulatory matters may change in the future as a result of new developments, including, but not limited to, the occurrence of new legal matters, changes in the law or regulatory environment, adverse or favorable rulings, newly discovered facts relevant to the matter, or changes in the strategy for the matter. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Contract Class Action and Opt Out Lawsuits. Beginning on March 12, 2013, the Company was served with several class action complaints filed in federal and state courts in several jurisdictions. These complaints asserted, among other things, that the Company had imposed unauthorized or excessive price increases and other charges on its customers in breach of its contracts and in violation of the Illinois Consumer Fraud and Deceptive Business Practices Act. The complaints sought certification of the lawsuit as a class action and the award to class members of appropriate damages and injunctive relief. These related actions were ultimately transferred to the United States District Court for the Northern District of Illinois for centralized pretrial proceedings. The parties reached a settlement agreement, as previously disclosed, which obtained court approval on March 8, 2018. Under the terms of the SQ Settlement, the Company admitted no fault or wrongdoing whatsoever, and it entered into the SQ Settlement to avoid the cost and uncertainty of litigation. Certain class members who have opted out of the SQ Settlement have filed lawsuits against the Company, and the Company has reached a settlement in principle with the plaintiffs in the remaining opt out actions, subject to documentation. The Company has made an accrual in respect of these collective matters consistent with its accrual policies described above, which is not material. Government Investigations. As previously reported, the Company entered into a deferred prosecution agreement (“DPA”) with the DOJ in 2022 in connection with its resolution of investigations by the DOJ, SEC, and various authorities in Brazil relating to the Company’s compliance with the FCPA and other anti-corruption laws with respect to operations in Latin America. Under the DPA, the DOJ agreed to defer criminal prosecution of the Company for a period of three years for charges of conspiring to violate the anti-bribery and books and records provisions of the FCPA. If the Company remains in compliance with the DPA during its -year term, the deferred charge against the Company will be dismissed with prejudice. Under the Company's settlement with the SEC, the Company entered into an administrative resolution with the SEC with respect to violations of the anti-bribery, books and records and internal controls provisions of the FCPA. The Company also agreed to pay fines, penalties and disgorgement to the DOJ, SEC and various Brazil authorities in a total amount of approximately $90 million. In April 2023, the last settlement with a foreign authority obtained final approval. In the second quarter of 2023, the Company substantially completed its payment obligations under the settlements. In addition, under the settlements with the DOJ and with the SEC, the Company has engaged an independent compliance monitor for two years and will undertake compliance with self-reporting obligations for an additional year. The Company is cooperating with an investigation by the office of the United States Attorney for the Southern District of New York (“SDNY”) and the United States Environmental Protection Agency into the Company’s historical compliance with federal environmental statutes, including the Resource Conservation and Recovery Act, in connection with the collection, transportation and disposal of hazardous waste by the Company’s former Domestic Environmental Solutions business unit. The Company has made an accrual in respect of this matter consistent with its accrual policies described above, which is not material. The Company understands that the SDNY investigation discussed above also concerned allegations of False Claims Act (“FCA”) violations made in a qui tam action filed under seal in the United States District Court for the Southern District of New York, purportedly on behalf of the United States, California and several other states. The Company understands that the United States, California, and the other states named in the qui tam action have completed their investigations into alleged FCA violations and have declined to participate in the qui tam action. The Company has not been served with the qui tam Complaint but intends to defend itself vigorously if the qui tam relator pursues its action. The Company has not accrued any amounts in respect of this action and cannot estimate the reasonably possible loss or any range of reasonably possible losses that the Company may incur. The Company is unable to make such an estimate because, based on what the Company knows now, in the Company’s judgment, the factual and legal issues presented in this matter are sufficiently unique that the Company is unable to identify other circumstances sufficiently comparable to provide guidance in making estimates. Environmental, Regulatory and Indemnity Matters. The Company is subject to various federal, state and local laws and regulations. In the ordinary course of business, we are routinely involved in government enforcement proceedings, private lawsuits, and other matters alleging non-compliance by the Company with applicable law. The issues involved in these proceedings generally relate to alleged violations of existing permits or other requirements, or alleged liability due to our current operations, pre-existing conditions at the locations where we operate, and/or successor or predecessor liability associated with our portfolio optimization strategy. From time to time, the Company may be subject to fines or penalties in regulatory proceedings relating primarily to waste treatment, storage or disposal facilities. Enviri Indemnification. Effective April 6, 2020, the Company completed the divestiture of its Domestic Environmental Solutions business to Enviri Corporation. Pursuant to the Purchase Agreement, the Company may have liability under certain indemnification claims for matters relating to the Domestic Environmental Solutions business, including potentially with respect to the SDNY investigation described above, the DEA Investigation matter discussed below, and other matters. Consistent with its accrual policies described previously, the Company has made accruals on various of these matters, which are neither individually nor collectively material. Rancho Cordova, California, NOVs. On June 25 and 26, 2018, the California DTSC conducted a Compliance Enforcement Inspection of the Company’s former Domestic Environmental Solutions facility in Rancho Cordova, California. On February 14, 2020, DTSC filed an action in the Superior Court for the State of California, Sacramento County Division, alleging violations of California’s Hazardous Waste Control Law and the facility’s hazardous waste permit arising from the inspection. The Company has reached a settlement in principle with the DTSC, subject to final documentation, with respect to these claims and any potential claims stemming from the search warrant executed in conjunction with the DEA inspection of the Rancho Cordova facility described below. The Company has made an accrual in respect of the settlement consistent with its accrual policies described above, which is not material. Rancho Cordova, California, Permit Revocation. Separately, on August 15, 2019, the Company received from DTSC a written Intent to Deny Hazardous Waste Facility Permit Application for the Rancho Cordova facility. Following legal challenges, that DTSC action became final as of April 8, 2022, triggering an obligation to execute the closure plan set forth in the facility's permit. Consistent with its accrual policies described previously, the Company has made an accrual in the amount of its estimate of closure costs reasonably likely to be incurred and indemnified to Enviri under the Purchase Agreement, which is not material. DEA Investigation. On February 11, 2020, the Company received an administrative subpoena from the DEA, which executed a search warrant at the Company’s former Domestic Environmental Solutions facility at Rancho Cordova, California and an administrative inspection warrant at the Company’s former facility in Indianapolis, Indiana for materials related to the former Domestic Environmental Solutions business of collecting, transporting, and destroying controlled substances from retail customers (the “ESOL Retail Controlled Substances Business”). On that same day, agents from the DTSC executed a separate search warrant at the Rancho Cordova facility. Since that time, the U.S. Attorney’s Office for the Eastern District of California (“USAO EDCA”) has been overseeing criminal and civil investigations of the ESOL Retail Controlled Substances Business. The USAO EDCA has informed the company that the investigations relate to the Company’s operation and sale of its former ESOL Retail Controlled Substances Business, that the Company may have civil liability under the Controlled Substances Act related to that business, and that the USAO EDCA is continuing the criminal investigation of the Company for potential violations of the Controlled Substances Act and other federal criminal statutes. The Company is cooperating with the civil and criminal investigations, which are ongoing. The Company has not accrued any amounts in respect of these investigations and cannot estimate the reasonably possible loss or any range of reasonably possible losses that the Company may incur. The Company is unable to make such an estimate because, based on what the Company knows now, in the Company’s judgment, the factual and legal issues presented in this matter are sufficiently unique that the Company is unable to identify other circumstances sufficiently comparable to provide guidance in making estimates. European Retrovirus Investigations. In conjunction with Europol, governmental authorities of Spain and Portugal have conducted coordinated inspections of a large number of medical waste management facilities, including Stericycle facilities, relating to the transportation, management and disposal of waste that may be infected with the COVID-19 virus, and related matters. The inspections have resulted in proceedings in Spain, in which the Company is vigorously defending itself. The Company has not accrued any amounts in respect of these investigations, as it cannot estimate the reasonably possible loss or any range of reasonably possible losses that the Company may incur. The Company is unable to make such an estimate because, based on what the Company knows now, in the Company’s judgment, the factual and legal issues presented in this matter are sufficiently unique that the Company is unable to identify other circumstances sufficiently comparable to provide guidance in making estimates.
|
Insider Trading Arrangements |
3 Months Ended |
---|---|
Sep. 30, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) |
9 Months Ended |
---|---|
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation: The accompanying unaudited condensed consolidated financial statements include the accounts of Stericycle, Inc. and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company's condensed consolidated financial statements were prepared in accordance with U.S. GAAP and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries and majority-owned subsidiaries over which the Company exercises control. Outside stockholders' interests in subsidiaries are shown on the condensed consolidated financial statements as “Noncontrolling interests”. The accompanying unaudited condensed consolidated financial statements as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022, have been prepared pursuant to the rules and regulations of the SEC for interim reporting and, therefore, do not include all information and footnote disclosures normally included in audited financial statements prepared in conformity with U.S. GAAP. In the opinion of management, however, all adjustments, consisting of normal recurring adjustments necessary to present fairly the results of operations, financial position and cash flows have been made. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the 2022 Form 10-K. The results of operations for any interim period are not necessarily indicative of the results of operations to be expected for the full year or any other period.
|
Use of Estimates | Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Some areas where the Company makes estimates include allowance for doubtful accounts, credit memo reserves, contingent liabilities, asset retirement obligations, stock compensation expense, income tax assets and liabilities, accrued employee health and welfare benefits, accrued auto and workers’ compensation self-insured claims, leases, goodwill and held for sale impairment valuations. Such estimates are based on historical trends and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates. |
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Revenues Disaggregated by Service, Primary Geographical Regions and Timing of Revenue Recognition | The following table presents revenues disaggregated by service and reportable segments:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Total Contract Acquisition Costs | Total contract acquisition costs, net of accumulated amortization, were classified as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Allowance for Credit Loss Activity | The changes in allowance for doubtful accounts were reported as follows:
|
RESTRUCTURING, DIVESTITURES, AND ASSET IMPAIRMENTS (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Divestiture Losses (Gains) | Stericycle recognized the following International pre-tax Divestiture losses (gains), net in the Condensed Consolidated Statements of Income (Loss):
|
DEBT (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Long-Term Debt | The Company’s long-term debt consisted of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Weighted Average Interest Rates on Long Term Debt Excluding Capital Leases | The weighted average interest rates on long-term debt, excluding finance leases were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Outstanding Letters of Credit and the Unused Portion of Senior Credit Facility | Amounts committed to outstanding letters of credit and the unused portion of the Company's Senior Credit Facility were as follows:
|
EARNINGS (LOSS) PER COMMON SHARE (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Computation of Basic and Diluted Earnings (Loss) Per Share | The following table shows the effect of stock-based awards on the weighted average number of shares outstanding used in calculating diluted earnings (loss) per share:
(1)In periods of net loss, stock-based awards are anti-dilutive and therefore excluded from the loss per share calculation.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | Anti-dilutive stock-based awards excluded from the computation of diluted earnings (loss) per share using the treasury stock method include the following:
|
SEGMENT REPORTING (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Financial Information Concerning Company's Reportable Segments | The following tables show financial information for the Company's reportable segments (see Note 2 – Revenues from Contracts with Customers for segment revenues):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Reconciliation of Company's Primary Measure of Segment Profitability Adjusted Income from Operations to Income (loss) from Operations | The following table reconciles the Company's primary measure of segment profitability, Adjusted Income from Operations, to Income from operations:
|
REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Detail) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
|
Revenue from Contract with Customer [Abstract] | |||||
Deferred revenues | $ 65.1 | $ 65.1 | $ 7.9 | ||
Contract acquisition costs weighted average estimated period (in years) | 6 years 6 months | ||||
Amortized deferred sales incentive cost | $ 4.2 | $ 3.8 | $ 12.3 | $ 10.8 |
REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Total Contract Acquisition Costs (Detail) - USD ($) $ in Millions |
Sep. 30, 2023 |
Dec. 31, 2022 |
---|---|---|
Disaggregation of Revenue [Line Items] | ||
Total contract acquisition costs | $ 60.9 | $ 54.7 |
Other current assets | ||
Disaggregation of Revenue [Line Items] | ||
Total contract acquisition costs | 15.7 | 14.2 |
Other assets | ||
Disaggregation of Revenue [Line Items] | ||
Total contract acquisition costs | $ 45.2 | $ 40.5 |
REVENUES FROM CONTRACTS WITH CUSTOMERS - Allowance for Credit Loss (Details) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
|
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | ||
Beginning Balance | $ 53.3 | $ 43.3 |
Bad debt expense, net of recoveries | 10.1 | 25.4 |
Write-offs | (12.2) | (9.8) |
Other charges | (4.1) | (0.3) |
Ending Balance | 47.1 | $ 58.6 |
Brazil Operations | ||
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | ||
Other charges | $ (6.4) |
DEBT - Narrative (Detail) |
9 Months Ended | ||
---|---|---|---|
Sep. 30, 2023
USD ($)
|
Jun. 15, 2023
USD ($)
|
Dec. 31, 2022
USD ($)
|
|
Credit Agreement due 2026 | Line of credit | |||
Debt Instrument [Line Items] | |||
Maximum consolidated leverage ratio | 400.00% | ||
EBITDA requirement amount | $ 50,000,000 | ||
Leverage ratio | 2.84 | ||
Credit Agreement Amended June 2023 | |||
Debt Instrument [Line Items] | |||
Finance lease, maximum amount under debt agreement | $ 200,000,000 | ||
Level 2 | |||
Debt Instrument [Line Items] | |||
Estimated fair value of debt | $ 1,200,000,000 | $ 1,400,000,000 |
DEBT - Schedule of Outstanding Letters of Credit and the Unused Portion of Senior Credit Facility (Detail) - Senior credit facility - Line of credit - USD ($) $ in Millions |
Sep. 30, 2023 |
Dec. 31, 2022 |
---|---|---|
Debt Instrument [Line Items] | ||
Outstanding letters of credit under Credit Facility | $ 59.0 | $ 60.1 |
Unused portion of the Credit Facility | $ 1,095.8 | $ 985.7 |
INCOME TAXES - Additional Information (Detail) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
Income Tax Disclosure [Abstract] | ||||
Income tax expense | $ 4.8 | $ 5.1 | $ 19.1 | $ 16.4 |
Effective tax rate | 69.60% | 15.40% | (112.40%) | 40.20% |
EARNINGS (LOSS) PER COMMON SHARE - Computation of Basic and Diluted Earnings (Loss) Per Share (Detail) - shares shares in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
Earnings Per Share [Abstract] | ||||
Weighted average common shares outstanding - basic (in shares) | 92.5 | 92.2 | 92.4 | 92.1 |
Incremental shares outstanding related to stock-based awards (in shares) | 0.4 | 0.2 | 0.0 | 0.3 |
Weighted average common shares outstanding - diluted (in shares) | 92.9 | 92.4 | 92.4 | 92.4 |
EARNINGS (LOSS) PER COMMON SHARE - Schedule of Antidilutive Securities Excluded from EPS Calculation (Detail) - shares shares in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
Option awards | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive shares excluded from computation of diluted earnings (loss) per share (in shares) | 711 | 1,153 | 780 | 1,297 |
RSU awards | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive shares excluded from computation of diluted earnings (loss) per share (in shares) | 98 | 397 | 1 | 115 |
SEGMENT REPORTING - Narrative (Detail) |
9 Months Ended |
---|---|
Sep. 30, 2023
segment
| |
Segment Reporting [Abstract] | |
Number of operating segments (in segments) | 2 |
Number of reportable segments (in segments) | 2 |
SEGMENT REPORTING - Financial Information Concerning Company's Reportable Segments (Detail) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
Segment Reporting Information [Line Items] | ||||
Adjusted Income from Operations | $ 70.3 | $ 92.0 | $ 231.0 | $ 233.0 |
North America | ||||
Segment Reporting Information [Line Items] | ||||
Adjusted Income from Operations | 143.5 | 160.4 | 460.3 | 443.9 |
International | ||||
Segment Reporting Information [Line Items] | ||||
Adjusted Income from Operations | 8.9 | 7.4 | 27.6 | 27.2 |
Other Costs | ||||
Segment Reporting Information [Line Items] | ||||
Adjusted Income from Operations | $ (82.1) | $ (75.8) | $ (256.9) | $ (238.1) |
SEGMENT REPORTING - Reconciliation of Company's Primary Measure of Segment Profitability Adjusted Income from Operations to Income from Operations (Detail) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
Segment Reporting [Abstract] | ||||
Total Reportable Segment Adjusted Income from Operations | $ 70.3 | $ 92.0 | $ 231.0 | $ 233.0 |
ERP and System Modernization | (4.8) | (3.9) | (12.9) | (13.0) |
Intangible Amortization | (27.9) | (31.5) | (84.2) | (94.7) |
Portfolio Optimization | (5.0) | (1.4) | (64.8) | (2.7) |
Litigation, Settlements and Regulatory Compliance | (5.3) | (2.6) | (22.4) | (26.0) |
Asset Impairments | (3.1) | (2.0) | (6.5) | (2.0) |
Income from operations | $ 24.2 | $ 50.6 | $ 40.2 | $ 94.6 |
COMMITMENTS AND CONTINGENCIES - Narrative (Details) - Government Investigations $ in Millions |
9 Months Ended |
---|---|
Sep. 30, 2023
USD ($)
| |
Loss Contingencies [Line Items] | |
Compliance monitor period | 2 years |
US Securities And Exchange Commission, Department Of Justice, and Brazilian Authorities | |
Loss Contingencies [Line Items] | |
Settlement amount | $ 90 |
Department Of Justice | |
Loss Contingencies [Line Items] | |
Deferred prosecution period | 3 years |
C&;3'=G0!95?=Y\XW(TJ+V&4T%1$+$6<
MKF\&M^9U@'%FD"/^C.B+:%RCC,J2L7^RF_OP9F!D,Z(Q7 DUL,X55KZMWS,JOICQ7X=*OXWH*(\LV=4 ($5 @:9M@1L;@=X ,8L
MR&C\[IA>OZ5-/!^?Z%]=[::6/5;P(-@O2G29>!\\1"#'#=-;JRC1SE]J7LM#1/J '?^V
M>M_)9?NGZZ20I:"FD,JBX,8JP4B0:TSS%Z;I)M.R8KK>.UZ^@[_I=WB_E &ULK55=
M3]LP%/TK5QF:0!I-FGY06!MIM$-# JVB8WN8]N FMZV%8V?V30O_?K:3A@(%
M\;"7QA_G')]S_='A1ND[LT(DN,^%-*-@152*(>I
MK5MCXU"E-[<95&T&IR9N$^;*Z=6!/,5@';U3&IU$V2VC[+8*\4YL"4/!B0+S
M<(O@1ZJPN^>4WSG!W'.">6<".UF87KDPO5;YS?:,D31X1I $4A[C_$X0_@WG
MF
ZG-
M/030\IOC4V&F$>I-',(T<4,_
U".?R#+7*]QR"CPQRH/(A'+D2*:11FWD/P5>_7AX^*:>
M8\^^Z:?88+&\O?]^-WM
K(0VN<_SK+6I^RI
M:^H716R/,R-4=(QM4)YLT2*X1+-@] D?>1VZO,7,S+3\"ZGUAFAK0K3X("E[
M*%[/QVL0J(C)_=ZJWW5_:;2JT,[" ,D_P$;[.&5U7[L9]22.9L_B<<"]%'8F
MJ6\J+$AUT-O;3<#&H3%NO*G#H#8UGL:^L"QISD;+ G1>&/IA+39LH)O
HM8N71-P]7#^>HEZB8*_N//TY?+SFF'S-63MPK2^^CUGZH8T##C
MS:(@R?\GK\6Y_0Z9K9(T6A2-=0\6?KC^Z?U63,16 \VI;T"+!G2WP> [#5C1
M@.W;8% T&.S;8%@T&.X[AE'18+1OA''18)PG:SV[>6I<+_4F%W'T2N+L;$W+
M7N3YS5OKC/AA5HK3--:_]76[='+/IP_WCSWG^1'XMY^T0=N]5L^_4BN
M/KGD:CKE#^3V[O/5[?T=__0P)2?$U=63I'ZZBA7Y.4H2E9 /4I=]\B/YX*K4
M\P/]ZH0\3EWRX8TU[8VY]9VO?T=&WFC+[-V36U J=JV26L_Y'0/F4U_;FQ-_]I%5J;
MN_;F=UZLFSO?;<[W[SRMF\SWC5W^W]&-5+!-^;*>GBV"IPG2V^F+COZ8SXG=B9_
M_YLSZO^C+NM(F(N$<21,(&$2!#-J9["IG8&-/LD^NN-8A;/?21I[89(=C,*Z"EJ'&.4ALF7_VX1U=6%_VRX,:S?:%@82
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MFV
ZWT+)41,D7_(
M!_?8(W,6QYHG%_G3*QJRF*GG(Q)M@#"N%_=Q;C%\MI0 R$Z5#>NQMHTRQJ$/
MG--T34,86WBBI" ?P9K\^HOK.[^U):DC9XV4]NC4@,Y3/71K@%VZ
M7ZW="C>AFL9]*79$&FMD,PVKOD6C7JPP^V2N)